At the 18th International Conference on Malignant Lymphoma (18ICML) and the European Hematology Association (EHA) 2025 meetings, multiple clinical trials presented new data on therapies for various lymphoma subtypes, including diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and marginal zone lymphoma (MZL). Key findings include the phase III POLARGO trial showing improved median overall survival (OS) of 19.5 months with Pola-R-GemOx versus 12.5 months with R-GemOx in transplant-ineligible relapsed/refractory (R/R) DLBCL patients. The phase III GOLSEEK-1 study evaluated golcadomide plus R-CHOP versus placebo plus R-CHOP in untreated high-risk large B-cell lymphoma, with progression-free survival (PFS) as the primary endpoint. The ATALANTA-1 study of GLPG5101, a fresh, stem-like anti-CD19 CAR T-cell therapy, demonstrated complete response (CR) and minimal residual disease (MRD) rates of 91% and 100%, respectively, in R/R indolent non-Hodgkin lymphoma (NHL). The phase Ib trial of JNJ-90014496, a CD19/CD20 bispecific CAR T-cell therapy, showed an overall response rate (ORR) of 95% and CR rate (CRR) of 80% in R/R large B-cell lymphoma (LBCL). The phase III ALPINE trial reported sustained benefits of zanubrutinib over ibrutinib in R/R CLL/SLL, with 36-month PFS of 67.4% versus 56.3% and ORR of 88.4% versus 76.6%. The SEQUOIA trial arm D showed that zanubrutinib plus venetoclax achieved 24-month PFS of 92% and peripheral blood undetectable MRD (uMRD) rate of 59% in treatment-naïve CLL/SLL. The STARGLO phase III trial demonstrated that glofitamab plus GemOx reduced the risk of progression or death by 59% compared to rituximab plus GemOx in R/R DLBCL, with median OS not evaluable versus 13.5 months. Other notable results include the phase II VALYM study of valemetostat monotherapy in R/R follicular lymphoma with ORR of 62%, the phase II Epi-RCHOP trial combining tazemetostat with R-CHOP in frontline follicular lymphoma showing 53.2% complete metabolic response, and the EPCORE NHL-2 trial of epcoritamab plus R-ICE in R/R DLBCL eligible for autologous stem cell transplant reporting ORR of 87% and CR rate of 65%. These studies collectively highlight advances in targeted therapies, CAR T-cell treatments, and combination regimens across lymphoma subtypes, with improved survival outcomes and manageable safety profiles.